4 friends from Cambridge built a desktop printer that lets scientists print their own proteins  — TFN

Nuclera, a biotech company developing protein printers, has secured $42.5 million in Series B funding. The company's benchtop printers aim to revolutionize medical and bioresearch by significantly reducing the time required to produce proteins. This advancement is crucial for accelerating drug development and tackling future pandemics. The funding will support the company's growth and expansion.

Nuclera Secures $42.5 Million for Protein Printing Revolution

Nuclera is a biotech company developing state-of-the-art protein printers that are revolutionizing the pharmaceutical and biotechnology industries. Their benchtop protein printers are revolutionizing medical and cutting-edge bioresearch. The company is working to eliminate issues that are slowing down vital research, such as the time it takes to grow proteins in the required quantities.

A biotech company developing state-of-the-art protein printers for the pharmaceutical and biotechnology industries.

3 years ago

Nuclera Secures $42.5 Million for Protein Printing Revolution

Covered on